EcoDrugPlus

Phosphodiesterase 3a

Ensembl ID : ENSSLDG00000004086
Gene Symbol: PDE3A
4 Cross references
195 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSSLDG00000015229
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSSLDG00000014021
Gene Symbol: PDE4A
3 Cross references
197 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSSLDG00000003622
Gene Symbol: PDE4B
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSSLDG00000020645
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSSLDG00000013675
Gene Symbol: PDE5A
3 Cross references
221 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSSLDG00000005138
Gene Symbol: PDE7A
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSSLDG00000005080
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSSLDG00000002241
Gene Symbol: PDE9A
3 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSSLDG00000016135
Gene Symbol: PIK3R1
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSLDG00000014985
Gene Symbol: PIK3R3
3 Cross references
163 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSLDG00000020141
Gene Symbol: PIK3R3
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).